ticlopidine has been researched along with Sclerosis, Systemic in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ntelis, K | 1 |
| Gkizas, V | 1 |
| Filippopoulou, A | 1 |
| Davlouros, P | 1 |
| Alexopoulos, D | 1 |
| Andonopoulos, AP | 1 |
| Daoussis, D | 1 |
1 trial available for ticlopidine and Sclerosis, Systemic
| Article | Year |
|---|---|
Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Animals; Clopidogrel; Endothelium, Vascular; | 2016 |